Participatory syndromic surveillance of influenza in Europe by Guerrisi, Caroline et al.
	 1	
Participatory	syndromic	surveillance	of	influenza	in	Europe	1	
Caroline	Guerrisi1,	Clément	Turbelin1,	Thierry	Blanchon1,	Thomas	Hanslik1,2,	Isabelle	2	 Bonmarin3,	Daniel	Levy-Bruhl3,	Daniela	Perrotta4,	Daniela	Paolotti4,	Ronald	3	 Smallenburg5,	Carl	Koppeschaar5,	Ana	O.	Franco6,	Ricardo	Mexia7,	W.	John	Edmunds8,	4	 Bersabeh	Sile9,	Richard	Pebody9,	Edward	van	Straten10,	Sandro	Meloni11,	Yamir	5	 Moreno11,	Jim	Duggan12,	Charlotte	Kjelsø13,	Vittoria	Colizza1,4*		6	
1)	Sorbonne	Universités,	UPMC	Univ	Paris	06,	INSERM,	Institut	Pierre	Louis	d’Epidémiologie	et	de	Santé	Publique	7	 (IPLESP),	Paris,	France	8	 2)	Assistance	Publique	Hopitaux	de	Paris,	Service	de	Medecine	Interne,	Hopital	Ambroise	Pare,	Boulogne	Billancourt,	9	 France	10	 3)	Department	of	infectious	diseases,	Public	Health	France,	St	Maurice	Cedex,	94415,	France	11	 4)	Institute	for	Scientific	Interchange	(ISI),	Turin,	Italy	12	 5)	Science	in	Action	BV,	Amsterdam,	the	Netherlands	13	 6)	Instituto	Gulbenkian	de	Ciência,	Oeiras,	Portugal	14	 7)	Instituto	Nacional	de	Saúde	Doutor	Ricardo	Jorge,	Lisbon,	Portugal	15	 8)	London	School	of	Hygiene	and	Tropical	Medicine,	London,	United	Kingdom	16	 9)	Public	Health	England,	London,	United	Kingdom	17	 10)	Public	Health	Agency	of	Sweden,	Stockholm,	Sweden	18	 11)	Institute	for	Biocomputation	and	Physics	and	Complex	Systems,	University	of	Zaragoza,	Spain	19	 12)	College	of	Engineering	and	Informatics,	National	University	of	Ireland,	Galway,	Ireland	20	 13)	Statens	Serum	Institute,	Copenhagen,	Denmark	21	 	22	 *Corresponding	author	23	 Vittoria	Colizza	24	 UMR-S	1136	Inserm	&	UPMC	25	 Institut	Pierre	Louis	d’Epidémiologie	et	de	Santé	Publique	26	 27	rue	Chaligny	27	 75012	Paris,	France	 	28	 Phone	number:	+33	1	44	73	84	59 29	 Fax:	+33	1	44	73	84	62	30	 	31	
Word	count:	Abstract	=	149;	Text	=	3,103	32	
	 	33	
	 2	
Abstract		34	
The	growth	of	digital	communication	technologies	for	public	health	is	offering	an	35	 unconventional	means	to	engage	the	general	public	in	monitoring	community	health.	36	 Here	we	present	Influenzanet,	a	participatory	system	for	the	syndromic	surveillance	of	37	 influenza-like-illness	in	Europe.	Through	standardized	online	surveys,	the	system	38	 collects	detailed	profile	information	and	self-reported	symptoms	volunteered	by	39	 participants	resident	in	the	Influenzanet	countries.	Established	in	2009,	it	now	includes	40	 ten	countries	representing	more	than	half	of	the	EU-28	population.	The	experience	of	41	 seven	influenza	seasons	illustrates	how	Influenzanet	has	become	an	adjunct	to	existing	42	 ILI	surveillance	networks,	offering	coherence	across	countries,	inclusion	of	non-43	 medically	attended	ILI,	flexibility	in	case	definition,	and	allowing	individual-level	44	 epidemiological	analyses	generally	not	possible	in	standard	systems.	Having	the	45	 sensitivity	to	timely	detect	substantial	changes	in	population	health,	Influenzanet	has	46	 the	potential	to	become	a	viable	instrument	for	a	wide	variety	of	applications	in	public	47	 health	preparedness	and	control.	48	
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Influenza	surveillance	in	Europe	54	
Seasonal	influenza	is	a	contagious	respiratory	disease	that	annually	infects	55	 approximately	10	to	30%	of	Europe’s	population,	causing	increased	hospitalization	56	 rates	and	excess	deaths	during	winter	[1]	.	Influenza	surveillance	is	conducted	by	57	 Member	States	and	coordinated	by	the	European	Center	for	Disease	Prevention	and	58	 Control	(ECDC)	via	the	European	Influenza	Surveillance	Network	(EISN).	EISN	combines	59	 epidemiological	and	virological	data	obtained	at	different	layers	of	surveillance.	60	 Nationally	organized	networks	of	general	practitioners	(GPs)	constitute	the	basis	of	61	 public	health	surveillance	(Figure	1a),	reporting	the	weekly	number	of	patients	visited	62	 with	influenza-like-illness	(ILI)	or	acute	respiratory	infection	(ARI)	in	selected	63	 healthcare	facilities	(sentinels).	Some	countries	also	report	virological	information	from	64	 a	subset	of	patients,	influenza-confirmed	hospitalizations	or	mortality	data.	The	aim	of	65	 collating	data	from	different	layers	of	surveillance	is	to	better	assess	the	intensity	and	66	 spread	of	influenza,	identify	trends	and	risk	groups,	and	inform	actions	to	reduce	the	67	 influenza-associated	burden	in	Europe.	68	
The	increased	use	of	digital	communication	technologies	for	public	health	[2]		has	69	 recently	facilitated	adding	the	general	public	as	a	key	actor	for	surveillance,	enabling	70	 individuals	to	contribute	to	monitoring	the	health	of	their	community.	The	result	is	a	71	 large	amount	of	crowdsourced	digital	data	that	can	be	rapidly	analyzed	to	track	disease	72	 activity	directly	in	the	general	population,	thus	providing	health	authorities	with	an	73	 additional	and	potentially	scalable	layer	of	surveillance	(Figure	1a).	Participatory	74	 systems	generally	rely	on	individuals’	self-assessment	of	their	health.	ILI	has	thus	75	 offered	a	straightforward	surveillance	objective	for	the	early	development	of	these	76	
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systems	[3–7]	,	given	its	seasonal	occurrence,	its	large	incidence	in	the	population,	and	77	 the	set	of	easily	recognizable	clinical	symptoms	that	it	may	cause	[8]	.	78	
The	Influenzanet	participatory	surveillance	system	was	established	in	Europe	in	2009	79	 and	included	a	total	of	five	countries	(Figure	1b),	four	of	which	(the	Netherlands,	80	 Belgium,	Portugal,	Italy)	had	already	prior	web-based	participatory	surveillance	81	 experience	[4]	.	The	system	is	based	on	online	survey	technology	to	conduct	syndromic	82	 surveillance	through	self-reported	symptoms	volunteered	by	participants	resident	in	83	 the	Influenzanet	countries.	It	is	based	on	a	website	describing	the	system,	its	objectives	84	 and	main	results	(www.influenzanet.eu),	and	pointing	to	the	national	web	platforms	85	 responsible	for	data	collection	for	national	surveillance.	These	platforms	collect	86	 background	demographic	and	risk-factor	data	from	participants	upon	enrolment	and	87	 their	weekly	symptoms,	and	report	analyzed	surveillance	results.	88	
At	its	start,	the	Influenzanet	platform	was	not	homogeneous	across	countries	because	of	89	 historical	developments	leading	to	the	project	[4]	.	It	was	built	on	the	Dutch	and	Belgian	90	 experience	of	de	Grote	Griepmeting	(The	Great	Influenza	Survey)	launched	during	the	91	 2003-2004	influenza	season	[3]	.	The	system	was	next	adopted	by	Portugal	(2005)	and	92	 Italy	(2008)	with	a	different	technological	platform	though	similar	survey.	The	aim	of	93	 Influenzanet	was	to	establish	a	standardized	syndromic	surveillance	system	across	94	 European	countries,	from	both	a	technological	and	epidemiological	point	of	view.	95	 Standardized	technology	is	crucial	for	the	seamless	introduction	of	the	system	in	a	new	96	 country,	thus	minimizing	costs	and	technological	challenges	in	the	implementation	and	97	 adaptation	to	a	different	population	(e.g.	language,	content,	server),	while	ensuring	high	98	 functionality	and	usability.	A	standardized	epidemiological	survey	is	needed	to	99	 maximize	coherence	across	national	surveillance	networks	and	thus	overcome	the	100	
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differences	in	case	definitions,	population	under	surveillance	and	data	formats	across	101	 countries,	currently	present	in	sentinel	influenza	surveillance	in	Europe	[1]	.		102	
The	first	Influenzanet	season	(2009-2010)	was	rather	unusual	as	it	was	characterized	by	103	 the	spread	of	the	2009	H1N1pdm.	Technological	development	of	Influenzanet	was	104	 halted	to	give	priority	to	ILI	surveillance	through	intensified	recruitment	efforts	and	105	 surveillance	during	Summer	2009.	By	the	start	of	the	2011-2012	influenza	season,	the	106	 Influenzanet	standardized	framework	was	ready	and	implemented	in	all	countries.		107	
Since	its	launch	in	2009,	Influenzanet	has	doubled	the	number	of	participating	countries,	108	 now	representing	36%	of	the	EU-28	Member	States	and	more	than	half	(58%)	of	the	EU-109	 28	population.	Its	web	approach	has	the	ability	to	generate	data	from	the	general	110	 population	and	not	only	from	medically	attended	ILI.	Its	crowdsourced	data	offer	111	 flexibility	for	the	exploration	of	different	ILI	or	ARI	case	definitions,	provide	detailed	112	 information	to	profile	the	population	under	surveillance,	estimate	vaccine	coverage	or	113	 assess	ILI-associated	behaviors.	Its	standardized	framework	and	centralized	European	114	 database	allow	for	country	level	analyses	and	rapid	extension	to	the	European	level,	115	 maintaining	identical	criteria	and	definitions.	Here	we	review	the	Influenzanet	116	 surveillance	system	since	its	launch,	summarize	main	findings	and	limitations,	present	a	117	 new	study	on	ILI	risk	factors	as	an	example	application,	discuss	Influenzanet	value	for	118	 public	health,	and	explore	its	future	developments.		119	
Influenzanet	system:	data	collection,	management,	and	analyses	120	
Participation	in	Influenzanet	is	voluntary	and	anonymous,	and	open	to	all	residents	of	121	 participating	countries.	Recruitment	occurs	through	communications	of	supporting	122	 institutions,	mainstream	and	social	media,	dissemination	events	(e.g.	science	fairs	or	123	 school	dissemination	activities)	and	word	of	mouth	(social	media	or	email	invitations	124	
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through	the	system).	In	some	countries,	weekly	reports	on	Influenzanet	results	are	also	125	 published	within	the	national	surveillance	bulletins.		126	
To	join	the	network,	individuals	register	on	their	national	platform	and	complete	an	127	 intake	survey	covering	demographic,	geographic,	socio-economic	(household	size	and	128	 composition,	occupation,	education,	transportation),	and	health	indicators	(vaccination,	129	 diet,	pregnancy,	smoking,	underlying	medical	conditions).	The	intake	survey	can	be	130	 updated	throughout	the	season	to	account	for	changes	(e.g.	vaccination	or	pregnancy).	131	 Multi-user	accounts	are	also	available	to	facilitate	group	participation	and	report	for	132	 children,	or	elderly	not	familiar	with	the	Internet.		133	
Crowdsourced	symptoms	data	are	obtained	on	a	weekly	basis	through	a	symptom	134	 survey.	Participants	are	asked	if	they	experienced	any	of	the	following	symptoms	since	135	 their	last	survey	(or	‘no	symptoms’):	fever,	chills,	runny	or	blocked	nose,	sneezing,	sore	136	 throat,	cough,	shortness	of	breath,	headache,	muscle/joint	pain,	chest	pain,	feeling	tired	137	 or	exhausted,	loss	of	appetite,	colored	sputum,	watery/bloodshot	eyes,	nausea,	vomiting,	138	 diarrhea,	stomach	ache,	other	symptoms.	If	symptoms	are	reported,	further	questions	139	 are	asked	to	assess	the	syndrome	(e.g.	sudden	onset,	temperature	measure)	and	140	 participant	behavior	(e.g.	health-seeking	behavior,	medicines	uptake	including	141	 painkillers	or	antipyretics,	cough	medications,	antivirals,	antibiotics).		142	
The	list	of	symptoms	was	chosen	to	include	the	various	ILI	definitions	adopted	by	143	 national	surveillance	systems	in	Europe.	Moreover,	following	the	2009	H1N1pdm	144	 experience,	we	decided	to	enlarge	the	list	to	include	also	gastroenterological	symptoms.	145	 The	aim	was	to	get	a	comprehensive	list	of	symptoms	that	could	be	clearly	articulated	146	 and	understood	by	participants,	and	that	would	enable	us	to	distinguish	within	a	range	147	 of	potentially	flu-related	illnesses.	148	
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Individuals	can	access	and	fill	the	survey	at	any	time,	and	are	reminded	weekly	by	a	149	 newsletter	also	summarizing	Influenzanet	findings.	Additional	questions	can	be	150	 implemented	by	countries	for	specific	studies.	Crowdsourced	data	are	analyzed	in	real	151	 time	and	national	and	regional	results	are	posted	on	the	system	websites.	They	are	also	152	 published	in	the	weekly	national	surveillance	bulletins	of	some	participating	countries	153	 (also	increasing	the	system’s	visibility	for	recruitment).	Targeted	and	more	local	154	 information	are	accessible	to	participants	only.		155	
Influenzanet	is	carried	out	by	Universities	and	Research	Institutions	(Italy,	Spain,	156	 Ireland),	Public	Health	Agencies	(United	Kingdom,	Sweden,	France,	Portugal,	Denmark),	157	 and	private	company	(Netherlands,	Belgium);	some	countries	transitioned	in	recent	158	 years	(United	Kingdom	and	Portugal	are	supported	by	Public	Health	Agencies	since	159	 2015).	Some	of	the	teams	are	also	members	of	the	EISN	(France,	Portugal,	Sweden).	160	 Influenzanet	is	conducted	in	agreement	with	national	regulations	on	privacy	and	data	161	 collection	and	treatment	[9]	.	162	
Influenzanet	surveillance	season	generally	runs	from	October/November	to	April/May,	163	 allowing	for	flexibility	(e.g.	press	conference	on	vaccination	campaign	to	increase	164	 dissemination	at	season	launch).	ILI	syndrome	assessment	is	built	on	the	basis	of	165	 reported	symptoms.	Influenzanet	uses	the	ECDC	case	definition	(sudden	onset	of	166	 symptoms;	at	least	one	of	fever	or	chills,	malaise,	headache	or	muscle	pain;	at	least	one	167	 of	cough,	sore	throat,	or	shortness	of	breath)	[8]	,	in	addition	to	country-specific	case	168	 definitions	to	allow	for	comparison	with	GP	surveillance	[10].		169	
Inclusion	criteria	for	participants	may	vary	depending	on	the	aim	of	the	study.	Several	170	 Influenzanet	works	[9,11–13]		included	participants	who	submitted	at	least	3	reports	171	 per	season,	whereas	a	more	constrained	definition	was	used	to	study	enrollment	172	
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strategies	[14]	.	Here,	for	the	analysis	of	ILI	risk	factors	we	included	participants	who	173	 reported	at	least	once	before,	during,	and	after	the	epidemic	period,	to	ensure	a	174	 minimum	participation	level	throughout	the	season.	We	considered	data	from	United	175	 Kingdom,	France,	Spain,	Ireland,	Denmark	in	the	2014-2015	season	and	use	ECDC	case	176	 definition	to	complete	previous	work	conducted	on	the	remaining	countries	[11,13].	177	 Odds	ratios	(ORs)	were	calculated	for	the	covariates	collected	with	the	intake	survey	178	 based	on	a	multivariate	logistic	regression	model	through	a	backward	stepwise	179	 selection.	As	the	ILI	outcome	is	not	a	rare	event,	we	also	corrected	ORs	to	estimate	the	180	 relative	risk	(RR)	and	95%	confidence	intervals.	Additional	details	are	provided	in	Table	181	 1.		182	
Influenzanet	results	and	discussion	183	
Since	the	launch	of	Influenzanet,	a	total	of	243,109	individuals	(considered	184	 independently	per	season)	joined	the	system	completing	the	intake	survey	and	185	 reporting	at	least	once.	Participation	across	seasons	saw	a	general	decrease	after	the	186	 pandemic	(Figure	1b,c),	visible	for	the	UK	and	statistically	significant	for	the	187	 Netherlands	and	Portugal	once	compared	to	their	previous	results	(average	number	of	188	 participants	per	season	before	vs.	after	2009:	20,597	vs.	15,564	𝑝 < 10!!,	and	3,447	vs.	189	 1,800	𝑝 = 0.003,	respectively,	Student	t-test).	This	may	be	a	reaction	to	the	substantial	190	 effort	required	to	participants	for	continued	surveillance	during	pandemic	season.	We	191	 argue	that	it	may	also	be	a	resulting	effect	of	the	controversies	over	vaccine	safety	and	192	 pandemic	management	[15],	fueling	public	dissonance	and	translating	into	negative	193	 experiences	for	individuals	[15–17]	.	The	effect	appears	to	rapidly	wane	in	the	194	 Influenzanet	system,	with	a	stabilized	number	of	Dutch	participants	(the	largest	195	 contribution	to	Influenzanet)	and	the	addition	of	new	countries	since	2011.		196	
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For	the	2015-2016	season,	Influenzanet	registered	36,192	participants	with	a	rate	of	197	 participation	of	13	per	100,000.	Participation	by	country	varies	considerably	[9]	,	with	198	 averages	over	all	seasons	ranging	from	1.2	per	100,000	(Spain)	to	almost	100	per	199	 100,000	for	the	Netherlands,	notably	the	most	successful	example	within	Influenzanet	200	 [18].	New	countries	have	shown	to	be	able	to	quickly	attract	a	large	enough	number	of	201	 participants	to	generate	reliable	surveillance	data	[10,19],	a	promising	result	for	further	202	 extending	the	system.	The	observed	heterogeneity	across	countries	may	be	associated	203	 with	diffused	trust	in	the	media	and	Internet,	larger	interest	of	the	general	public	in	204	 health-related	topics	and	larger	healthcare	expenditure	(ongoing	work).		205	
Recruitment	and	retention	are	the	two	main	challenges	for	Influenzanet.	TV	206	 appearances	at	the	early	stages	of	de	Grote	Griepmeting	and	dissemination	by	207	 communication	scientists	led	to	a	considerable	growth	of	participants,	successfully	208	 retained	across	years	[11,13].	By	comparison,	isolated	spikes	in	participation	indicating	209	 high	drop-out	rates	were	instead	observed	in	a	similar	participatory	system	in	the	210	 United	States	[5].	Continuous	reporting	throughout	the	season	is	essential	to	ensure	211	 data	quality.	Since	the	standardized	framework	is	in	place,	Influenzanet	collected	a	total	212	 of	2,694,065	symptom	reports	(up	to	April	2016),	543,895	in	the	last	season	with	a	213	 weekly	average	of	22,768	reports.	Participants	can	join	the	system	at	any	time	during	214	 the	surveillance	season	and	on	average	they	submit	14	to	16	reports	each	in	a	season.	215	 67-91%	of	them,	depending	on	the	country,	submitted	at	least	3	reports	in	season	2014-216	 2015,	with	small	variations	across	seasons	[9].	These	statistics	indicate	a	good	217	 compliance	for	reporting	that	can	be	due	to	various	factors:	strong	interest	in	being	218	 actively	engaged	in	a	health	project	[18],	and	rather	easy	access	and	use	of	the	219	 Influenzanet	platform	(>93%	of	French	and	Portuguese	participants	declared	that	220	 surveys’	length	was	good	and	>97%	of	them	were	satisfied	or	very	satisfied	with	the	221	
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website).	Individuals	with	a	higher	participation	were	found	to	be	recruited	more	likely	222	 through	offline	communication	than	through	online	media,	except	for	France	[14],	223	 where	a	considerable	fraction	of	participants	(21%)	is	referred	to	Influenzanet	from	224	 Institutional	Public	Health	websites.	Different	strategies	need	therefore	to	be	considered	225	 by	countries	to	promote	the	project	and	grow	in	participation.		226	
Statistically	significant	differences	exist	when	the	Influenzanet	cohort	is	compared	to	227	 national	populations	[9,10].	Higher	female	participation	occurs	in	the	majority	of	228	 countries,	as	in	other	studies	[5,7],	possibly	due	to	a	more	active	information-seeking	229	 behavior	in	women	[20]	.	All	age	classes	are	represented	in	the	cohort,	but	younger	(<30	230	 years)	and	older	(70+)	classes	are	considerably	underrepresented,	perhaps	for	lack	of	231	 interest	or	difficulty	of	access.	Specific	communication	activities	and	tools	(e.g.	for	232	 schools	and	senior	classes)	have	been	implemented	in	several	countries	to	target	these	233	 age	groups.	Also,	a	marked	increase	in	participation	of	the	elderly	has	been	observed	234	 over	the	years	[11],	likely	due	to	a	growing	Internet	usage	in	that	group,	suggesting	that	235	 discrepancies	may	decrease	in	time.	Vaccination	coverage	in	the	65+	age	class	is	236	 generally	higher	in	the	Influenzanet	population,	suggesting	a	higher	health	awareness	in	237	 the	cohort.	238	
Despite	these	discrepancies,	trends	of	estimated	ILI	incidence	from	Influenzanet	reports	239	 compare	well	with	those	of	national	sentinel	systems	[4,10,11,19,21]	.	An	anticipation	of	240	 about	1	week	in	the	peak	of	Influenzanet	incidence	is	found	compared	to	sentinel	241	 estimations,	suggesting	that	the	time	needed	to	consult	a	doctor	and	collate	sentinel	data	242	 may	be	absorbed	once	data	is	collected	directly	from	the	general	population	and	timely	243	 analyzed.	The	Influenzanet	cohort	has	also	been	used	to	estimate	vaccine	effectiveness	244	 in	real-time	[22],	vaccine	coverage	in	specific	subgroups	[23],	individual	perception	245	
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towards	vaccination	[17],	and	to	correct	estimations	of	pandemic	burden	accounting	for	246	 changes	in	social	contacts	patterns	and	in	health-seeking	behavior	[24,25].		247	
Most	importantly,	individual	data	on	demographic	indicators,	lifestyle	and	health	248	 variables,	and	the	monitoring	of	a	wide	variety	of	cases	allow	us	to	examine	risk	factors	249	 for	specific	conditions	to	a	detail	that	is	hardly	achievable	in	sentinel	systems.	The	250	 analysis	based	on	single	and	multiple	influenza	seasons	(Table	1)	suggests	that	251	 belonging	to	a	younger	age	group,	being	female,	living	with	or	having	contacts	with	252	 children,	having	an	underlying	chronic	health	conditions,	respiratory	allergies,	daily	253	 smoking	and	having	pets	are	factors	associated	with	an	increased	risk	of	having	an	ILI	254	 episode	during	influenza	season.	Vaccination	provided	a	reduction	in	the	risk,	though	it	255	 was	found	to	depend	on	the	season	[13].	Some	discrepancies	are	found	across	countries	256	 that	may	be	due	to	the	small	sample	sizes.	These	results	are	generally	consistent	with	257	 previous	findings	[26–28].	Children	are	known	to	have	a	major	role	in	the	dissemination	258	 of	influenza	[26].	Chronic	illness	was	found	to	be	a	major	driver	for	influenza	259	 complication	and	hospitalization	[27].	Cigarette	smoking	represents	a	substantial	risk	260	 factor	for	important	bacterial	and	viral	infections	[28].	In	addition,	we	found	that	261	 women	have	an	increased	risk	in	all	countries	and	seasons	under	study,	even	when	262	 adjusting	for	living	or	having	contacts	with	children.	Though	this	risk	factor	was	not	263	 reported	by	GP	surveillance,	it	was	found	in	previous	cohort	studies	also	in	adults	264	 without	children	[26].	It	would	be	interesting	to	explore	whether	such	gender	265	 differential	is	not	observed	in	routine	GP	surveillance	due	to	differences	in	health-266	 seeking	behavior	between	men	and	women.	This	is	not	observed	in	self-reporting	in	267	 many	Influenzanet	countries,	thus	other	factors,	such	as	unmeasured	confounders,	may	268	 be	at	play.	Daily	use	of	public	transport	was	not	statistically	associated	with	a	higher	risk	269	
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of	contracting	ILI,	contrary	to	widespread	public	concerns.	This	is	in	line	with	previous	270	 work	for	the	risk	of	ARI	once	frequent	use	is	considered	[29].	271	
Influenzanet	flexibility	allows	the	integration	of	additional	questions	for	specific	studies	272	 or	target	populations	that	are	usually	not	considered	in	routine	analyses.	A	study	of	273	 French	Influenzanet	pregnant	women	showed	a	higher	ILI	incidence	in	40+	women	and	274	 during	first/second	semester	[23].	Investigating	stress	indicators	revealed	significant	275	 trends	between	stress	and	self-reported	ILI	[30].	276	
Conclusions	277	
Influenzanet	is	a	well-established	standardized	participatory	surveillance	system	for	ILI	278	 in	Europe,	covering	more	than	one	third	of	EU-28	Member	States.	Its	strength	lies	in:	(i)	279	 the	standardized	technological	and	epidemiological	framework	for	a	coherent	280	 surveillance	across	countries;	(ii)	the	ability	to	timely	monitor	ILI	in	the	general	281	 population,	including	individuals	who	do	not	seek	medical	assistance;	(iii)	its	sensitivity	282	 in	detecting	substantial	changes	in	population	health	earlier	than	GP	sentinel	networks;	283	 (iv)	its	potential	scalability	to	large	numbers	with	rather	limited	costs;	(v)	its	flexibility	284	 in	exploring	different	ILI	definitions;	(vi)	the	detailed	profile	data	allowing	individual-285	 level	epidemiological	analyses	generally	not	possible	in	standard	systems;	(vii)	its	286	 potential	extension	to	other	diseases.	Its	limitations	are	mainly	due	to	the	self-selected	287	 sample,	potential	misreporting	and	lack	of	validation	by	a	medical	doctor	or	virological	288	 testing.	However,	the	agreement	found	with	GP	incidence	trends	suggests	that	these	289	 limitations	have	little	effect	once	results	are	adjusted	for	lack	of	representativeness.	290	
Immediate	steps	for	Influenzanet	include	the	extension	to	other	European	countries	and	291	 establishing	a	global	collaborative	framework	for	ILI	surveillance	with	other	similar	292	
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participatory	systems	outside	Europe.	Virological	confirmation	has	also	been	tested	in	293	 pilot	studies	for	future	integration.		294	
Main	challenges	remain	the	baseline	maintenance	resources	to	sustain	the	system	in	the	295	 long	run,	and	the	recruitment	and	retention	of	participants.	While	the	identification	of	296	 socio-cultural	determinants	for	participation	will	provide	additional	insights,	the	strong	297	 willingness	for	engagement	found	in	most	countries’	participants	confirms	the	feasibility	298	 of	the	approach.	Moreover,	the	platform	represents	a	crucial	channel	for	communication	299	 with	the	public,	to	inform	and	grow	awareness,	an	increasingly	important	aspect	after	300	 the	2009	pandemic.	301	
Launched	as	a	research	project,	Influenzanet	is	currently	considered	as	an	adjunct	to	302	 existing	ILI	surveillance	systems	and	has	been	adopted	in	some	cases	by	Public	Health	303	 Agencies.	Its	flexibility	in	system	configuration	potentially	allows	for	a	wide	variety	of	304	 applications	in	public	health	preparedness	and	control.	Sweden	for	example	has	tested	a	305	 different	method,	based	on	invitation	only,	in	the	last	two	seasons	to	track	the	health	306	 situation	of	the	country.	307	
Influenzanet	may	therefore	represent	a	viable	complement	to	existing	monitoring	308	 approaches	to	provide	additional	information	that	standard	methods	cannot	rapidly	309	 achieve.	Italy	is	now	extending	the	surveillance	effort	to	monitor	Zika	cases	with	the	310	 approaching	of	the	Summer.	In	France,	a	food	consumption	survey	submitted	to	311	 Influenzanet	participants	for	an	outbreak	investigation	during	a	Salmonella	epidemic	in	312	 early	2016	provided	public	health	authorities	with	timely	findings	to	identify	the	source	313	 of	the	outbreak.	With	the	large	majority	of	participants	willing	to	contribute	to	314	 additional	studies	beyond	ILI,	Influenzanet	may	become	in	the	near	future	a	powerful	315	 system	that,	once	adjusted	for	sample	biases,	can	offer	a	timely	‘thermometer’	316	
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measuring	the	epidemiological	status,	opinion	or	behavior	of	the	general	population	317	 along	different	indicators	and	diseases.		318	
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Table	1.	Adjusted	risk	factors	for	ILI	across	Influenzanet	countries	obtained	from	412	
multivariate	 regression	 analyses.	 The	 analysis	 for	 Denmark	 (981	 participants)	 and	413	 Spain	 (368	participants)	 for	 the	2014-2015	 season	 showed	 similar	 results	 for	 the	 age	414	 classes	(both	countries)	and	for	the	female	gender	(Denmark).	The	analysis	for	Ireland	415	 (210	participants)	for	the	same	season	did	not	show	significant	results.	416	
a	Except	vaccination	results	here	shown	for	2012-2013	season	417	
b	 Inclusion	 criteria	 in	 this	 study	 were	 slightly	 different:	 at	 least	 3	 symptoms	 survey,	 considering	 ILI	418	 episodes	during	the	weeks	when	influenza	strain	were	circulating	in	the	population.	419	
c	All	covariates	considered	as	potential	risk	factors	were	included	and	remained	in	the	final	multivariate	420	 model.	All	participants	were	considered	independent	between	seasons.	Only	vaccination	was	considered	421	 as	a	season-dependent	covariate,	and	country	of	residence	and	season	were	added	in	the	model	as	extra	422	 covariates.	423	
d	 All	 covariates	 collected	 in	 the	 intake	 survey	 were	 considered	 and	 included	 in	 the	 final	 multivariate	424	 analyses	 if	 they	 had	 univariate	 p-value	 <0.2.	 Backward	 stepwise	 selection	 was	 considered.	 A	 Hosmer-425	
Countries	 NL	+	BE	+	PT	+	IT	[13]	 UK		 FR	Study	period	 2003-2013a	 2014-2015	 2014-2015	#	of	participants	included	in	the	study	 Average	#	per	seasonb:	NL:	16,481					BE:	5,072	PT:			1,894						IT:		1,219	 2,629	 4,475	
Variable	 RR	(95%	CI)c	 RR	(95%	I)d	 RR	(95%	CI)d	
Female	gender	 1.22	(1.17-1.28)	 1.25	(1.14-1.36)	 1.12	(1.02-1.23)	
Vaccinated	 0.80	(0.71-0.91)	 –	 0.87	(0.78-0.97)	
Age	 <18	
18-49	
50-64	
65+	
1.59	(1.46-1.74)	*	0.82	(0.78-0.86)	0.46	(0.41-0.51)	
0-14	
15-44	
45-64	
65+	
1.27	(1.03-1.50)	*	0.99	(0.89-1.11)	0.82	(0.71-0.94)	
0-14	
15-44	
45-64	
65+	
0.95	(0.76-1.16)	*	0.87	(0.76-0.98)	0.68	(0.58-0.79)	
Household			 Living	w.	children	 1.31	(1.22-1.40)		(vs.	living	alone)	 –	 –	
Contacts	w.	groupse	 X	 1.11	(1.01-1.21)	 1.12	(1.01-1.23)	
Smoker	 1.16	(1.10-1.22)	 –	 –	
Underlying	
health	
conditions		
Asthmaf	Diabetes		Heart	Kidney	Immune	
1.58	(1.47-1.69)	1.27	(1.15-1.41)	1.29	(1.13-1.47)	1.23	(0.80-1.90)	1.23	(1.02-1.49)	
		–	 		Any:	1.17	(1.05-1.30)		
Having	respiratory	
allergies	 X	 1.14	(1.05-1.24)	 1.19	(1.07-1.29)	
Declaring		often		
having	ILI	 X	 X	 1.31	(1.17-1.45)	
Sports	>1h	per	week	 0.95	(0.90-1.00)	 X	 X	
Having	pets		 Dogs	Cats	 1.15	(1.09-1.22)	1.07	(1.02-1.12)	 X	 Any:	1.17	(1.08-1.28)	
Daily	
transport		 Bike/Foot	Car	Public		 0.95	(0.90-1.00)	*	0.97	(0.89-1.05)	 *	*	0.91	(0.78-1.05)	 	 –	
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Lemeshow	test	was	computed	to	estimate	the	 final	models	quality.	All	models	had	a	p-value	above	0.05	426	 suggesting	that	they	were	correctly	specified.	427	
e	Contacts	with	any	groups	of	children,	elderly,	patients	or	crowds	during	the	course	of	a	typical	day	428	
f	Asthma	or	other	lung	diseases	429	 *	Reference	category	430	 –	Significant	covariates	in	the	univariate	analyses,	but	not	selected	by	the	multivariate	logistic	regression	431	 (p>0.05).	Blank	cells	indicate	non-significant	variables	in	the	univariate	logistic	regression	analyses.	432	 X	not	available	data	433	 	434	
	 	435	
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Figure	legends	436	
	437	
Figure	1.	Influenzanet	participatory	surveillance	system	for	ILI.	(a)	ILI	monitoring	438	 scheme	illustrating	different	layers	of	surveillance	used	by	public	health	authorities,	439	 including	(depending	on	the	country)	sentinel	GP	networks	counting	ILI	visits,	ILI-440	 associated	hospitalization	data,	ILI-associated	mortality	data.	Influenzanet	represents	an	441	 additional	layer	for	ILI	monitoring,	through	syndromic	surveillance	in	the	general	442	 population	by	means	of	a	web-based	participatory	system.	It	includes	10	countries	443	 schematically	represented	in	the	map:	NL	(www.degrotegriepmeting.nl),	BE	444	 (www.degrotegriepmeting.be),	PT	(www.gripenet.pt),	IT	(www.influweb.it),	UK	445	 (flusurvey.org.uk),	SE	(www.halsorapport.se),	FR	(www.grippenet.fr),	ES	446	 (www.gripenet.es),	IE	(flusurvey.ie),	DK	(influmeter.dk).	(b)	Number	of	Influenzanet	447	 participants	per	country	per	season	since	its	launch	in	2009-2010	influenza	season.	The	448	 dashed	vertical	line	indicates	the	standardized	framework	introduced	from	the	2011-449	 2012	season.	(c)	Total	number	of	Influenzanet	participants	per	season	(left	vertical	axis)	450	 and	Influenzanet	rate	of	participation	per	season	(right	vertical	axis)	expressed	as	451	 number	of	participants	per	100,000	individuals	of	the	total	population	of	Influenzanet	452	 countries.	453	
